Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response.

Pharmacopsychiatry - 1 Sept 2022

Scherf-Clavel Maike, Weber Heike, Wurst Catherina, Stonawski Saskia, Hommers Leif, Unterecker Stefan, Wolf Christiane, Domschke Katharina, Rost Nicolas, Brückl Tanja, Lucae Susanne, Uhr Manfred, Binder Elisabeth B, Menke Andreas, Deckert Jürgen

Abstract excerpt

INTRODUCTION: Pharmacogenetic testing is proposed to minimize adverse effects when considered in combination with pharmacological knowledge of the drug. As yet, limited studies in clinical settings have investigated the predictive value of pharmacokinetic (pk) gene variation on therapeutic drug levels as a probable mechanism of adverse effects, nor considered the combined effect of pk gene variation and drug...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2D6

Share to Genotype

Share to Venlafaxine Hydrochloride

Source

Open in PubMed Open full text

Identifiers

PMID: 35839823
DOI: 10.1055/a-1872-0613
PMCID: PMC9458342

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of Pharmacokinetic Gene Variation on Therapeutic Drug Levels and Antidepressant Treatment Response.PMID 35839823Read ↗

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and FutureSemantic proximity Read ↗

Pharmacogenetic studies: a tool to improve antidepressant therapy.Semantic proximity Read ↗

Therapy response prediction in major depressive disorder: current and novel genomic markers influencing pharmacokinetics and pharmacodynamics.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants.Semantic proximity Read ↗

Pharmacogenetics testing for poor response to antidepressants: a transnosographic case seriesSemantic proximity Read ↗

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapySemantic proximity Read ↗

Pharmacogenetics-guided dose modifications of antidepressants.Semantic proximity Read ↗

Pharmacogenetics of antidepressant drugs: State of the art and clinical implementation - recommendations from the French National Network of Pharmacogenetics.Semantic proximity Read ↗

Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIsSemantic proximity Read ↗

Do we need pharmacogenetics to personalize antidepressant therapy?Semantic proximity Read ↗

Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.Semantic proximity Read ↗

Pharmacogenetics of mood disorders: what clinicians need to know.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.